These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 2697575

  • 1. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C.
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP, Ward D, Hemingway L, Hemstreet GP, Bradley E, Konrad M.
    Cancer Res; 1990 Oct 15; 50(20):6708-15. PubMed ID: 2208137
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 4. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E.
    Hinyokika Kiyo; 1992 Nov 01; 38(11):1305-9. PubMed ID: 1485586
    [Abstract] [Full Text] [Related]

  • 5. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A, Savona S, Gafney E, Penichet KO, Lin BY, Levitt D, Ahmed T, Arlin ZA, Baskind P, Needleman D.
    J Biol Response Mod; 1989 Oct 01; 8(5):468-78. PubMed ID: 2795092
    [Abstract] [Full Text] [Related]

  • 6. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
    Shiloni E, Pouillart P, Janssens J, Splinter T, Di Peri T, Symann M, Roest GJ, Palmer PA, Franks CR.
    Eur J Cancer Clin Oncol; 1989 Oct 01; 25 Suppl 3():S45-9. PubMed ID: 2697579
    [Abstract] [Full Text] [Related]

  • 7. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
    Stoter G, Shiloni E, Aamdal S, Cleton FJ, Iacobelli S, Bijman JT, Palmer P, Franks CR, Rodenhuis S.
    Eur J Cancer Clin Oncol; 1989 Oct 01; 25 Suppl 3():S41-3. PubMed ID: 2697578
    [Abstract] [Full Text] [Related]

  • 8. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH.
    J Clin Oncol; 1992 Feb 01; 10(2):275-81. PubMed ID: 1732429
    [Abstract] [Full Text] [Related]

  • 9. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, deKernion J, Belldegrun A.
    Cancer J Sci Am; 1997 Dec 01; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [Abstract] [Full Text] [Related]

  • 10. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA.
    Cancer Res; 1988 Oct 15; 48(20):5864-7. PubMed ID: 3139285
    [Abstract] [Full Text] [Related]

  • 11. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC, Rosenberg SA.
    Cancer J Sci Am; 1997 Dec 15; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [Abstract] [Full Text] [Related]

  • 12. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT, Osgood B, Barna B, Boyett JM, Finke J, Medendorp SV, Murthy S, Novak C, Sergi J, Tubbs R.
    Cancer Res; 1989 Nov 15; 49(22):6432-6. PubMed ID: 2804986
    [Abstract] [Full Text] [Related]

  • 13. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF, Aramendía JM, Alonso G, Foncillas JG, Brugarolas A.
    Rev Med Univ Navarra; 1996 Nov 15; 40(3):6-12. PubMed ID: 9499820
    [Abstract] [Full Text] [Related]

  • 14. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J, Kirchner H, Poliwoda H.
    Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():38-43. PubMed ID: 8692118
    [Abstract] [Full Text] [Related]

  • 15. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A, Menzel T, Körfer A, Heer G, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J.
    Nat Immun; 1992 Apr 12; 11(3):133-43. PubMed ID: 1392401
    [Abstract] [Full Text] [Related]

  • 16. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH.
    Br J Cancer; 2000 Feb 12; 82(4):772-6. PubMed ID: 10732744
    [Abstract] [Full Text] [Related]

  • 17. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S.
    Cancer Res; 1990 Nov 15; 50(22):7343-50. PubMed ID: 2224862
    [Abstract] [Full Text] [Related]

  • 18. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P, Bordin V, Vaghi M, Fumagalli L, Bordoni A, Mengo S, Bucovec R, Fumagalli E, Malugani F, Ardizzoia A, Giani L, Gardani GS, Tancini G.
    Anticancer Res; 2002 Nov 15; 22(2B):1061-4. PubMed ID: 12168901
    [Abstract] [Full Text] [Related]

  • 19. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT.
    N Engl J Med; 1987 Apr 09; 316(15):889-97. PubMed ID: 3493432
    [Abstract] [Full Text] [Related]

  • 20. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.
    J Urol; 2001 Jul 09; 166(1):68-72. PubMed ID: 11435825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.